Showing results (221-230 of 300) with videos related to

Sort By:
Pageof 30
Bone Marrow Transplantation|November 11, 2008
Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myelomaM A Gertz, S K Kumar, M Q Lacy, et al.
Bone Marrow Transplantation|October 30, 2012
Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioningL J DeCook, M Thoma, T Huneke, et al.
Leukemia|June 22, 2007
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myelomaS Kumar, A Dispenzieri, M Q Lacy, et al.
Blood Cancer Journal|January 16, 2016
Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemiaM M Patnaik, T L Lasho, P Vijayvargiya, et al.
Leukemia|October 15, 2010
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patientsD Caramazza, K H Begna, N Gangat, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 12, 2002
Variations in bone density among persons of African heritageL J Melton III, M A Marquez, S J Achenbach, et al.
American Journal of Clinical Oncology|October 16, 1999
Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemiaA Tefferi, R Levitt, C Y Li, et al.
Leukemia|September 14, 2011
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617FA Tefferi, T Jimma, N H Sulai, et al.
Blood Cancer Journal|August 8, 2015
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosisA Pardanani, A Tefferi, C Jamieson, et al.
Blood Cancer Journal|March 14, 2015
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trialA Pardanani, A Tefferi, P Guglielmelli, et al.
Pageof 30